QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Résumé Extracto Full Text PDF Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Articles Ahead of Print [Order Reprint] Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by González-Fernández, M. A. Articles by García-Consuegra, J. Search for Related Content PubMed PubMed Citation Articles by González-Fernández, M. A. Articles by García-Consuegra, J.

Polyarteritis Nodosa Resistant to Conventional Treatment in a Pediatric Patient

Clinical Pharmacist Specialist, Department of Pharmacy, Hospital Universitario La Paz, Madrid, Spain

Julia García-Consuegra, MD PhD

Clinical Pediatrician Specialist, Paediatric Rheumatology Department, Hospital Universitario La Paz

Reprints: María Angeles González-Fernández, Department of Pharmacy, Hospital La Paz, C/Nuremberg, n^º 7, 4^ºB, 28032 Madrid, Spain, fax 34-91-7277058, gonferan100{at}hotmail.com

OBJECTIVE: To report the case of a child diagnosed with polyarteritis nodosa (PAN) that was unresponsive to conventional treatment alone but improved with the addition of iloprost and bosentan to her drug regimen.

CASE SUMMARY: A 3-year-old girl who had been diagnosed with PAN was referred to our hospital from another region. With conventional treatment of high doses of a corticosteroid and cyclophosphamide, her condition resolved. Six months later, our patient had a relapse that required hospital admission. In this second hospital stay, some cutaneous lesions evolved into digital necrosis. Offlabel therapeutic alternatives, including a single dose (2 g/kg) of intravenous immunoglobulin (IVIG), intravenous iloprost 2 ng/kg/min over 6 h for 5 days and, approximately 4 wk later, oral bosentan 37.25 mg twice daily for 4 wk followed by 62.5 mg twice daily for 8 wk, were added to the conventional regimen to treat the serious cutaneous manifestations. Her fingers improved very slowly, and she was discharged on gradually tapered doses of oral corticosteroids, bosentan, and monthly pulsed injections of cyclophosphamide. The digital necrosis and other cutaneous lesions had resolved completely 6 months after the second discharge.

DISCUSSION: The dosages of IVIG and iloprost were based on those used for PAN, Raynaud's phenomenon, and digital necrosis in children. The use of bosentan for vasculitis had not been reported in children before the treatment of our patient, so its dosage was based on that used to produce vasodilation in children with pulmonary hypertension.

CONCLUSIONS: Digital necrosis and cutaneous manifestations not resolved with conventional PAN treatment improved within 5 days with iloprost and 12 weeks with bosentan.

Key Words: bosentan, corticosteroids, cyclophosphamide, iloprost, intravenous immunoglobulins, pediatrics, polyarteritis nodosa

Published Online, April 3, 2007. www.theannals.com, DOI 10.1345/aph.1H637

This article has been cited by other articles:

				R. Thonhofer, C. Siegel, F. Hafner, G. Gotschuli, and M. Brodmann Successful bosentan treatment of critical ischaemia induced by vasculitis in an SCLE patient Rheumatology, November 1, 2008; 47(11): 1729 - 1730. [Full Text] [PDF]